The technological basis underlying the Altis Osteogenic Matrix are the Bone Morphogenetic Proteins (BMP), a family of growth factors capable of inducing new bone formation commencing with days of implantation into human patients.
Play Info
Video
Video
The technological basis underlying Altis Osteogenic Bone Matrix(OBM) are the bone morphogenetic proteins (BMPs), a family of growth factors capable of inducing new bone formation commencing shortly after implantation into human recipients.
The company has also developed an injectable delivery system based entirely on bone matrix.
Altis OBM is an implant material intended as an alternative or substitute to traditional bone graft products, which usually involve the harvest of bone from the patient's own hip, or which employ allograft donor bone supplied by bone tissue banks. Altis OBM is injected into the skeletal site requiring regeneration of new bone, without the need to perform a second bone graft operation.
Altis OBM may offer a safe and effective alternative to traditional autogenous grafting procedures still in popular use today
The potential utility of Altis OBM is immediately obvious with respect to specific Skeletal conditions requiring bone healing and regeneration
"Altis OBM was easy to inject into traumatic bone defects, eliminating the trouble of harvesting autogenous bone graft.”
Doctor Marshall Murdoch, 2019
For customer complaint, AE and any other issue related to the product quality, feel free to call us on +27 012 844 0099 or send us an email to qa@altisbiologics.com
Here’s a roadmap of our product to highlight the milestones from the initial phase to delivery and future updates.
The company launches novel loadbearing cancellous bone graft Alti Graft. Also available in large dimension Alti Bloc.
Altis commences construction of new research and development laboratories focused on humanization research of xenogeneic bone into homogenous bone graft substitute.
The Company expands its production line attaining five-fold scale up production of bone morphogenetic protein complex and humanized bone matrix.
Altis commissions new bio-processing facilities at Bio Park, located within the Innovation Hib Industrial Complex in Pretoria.
Altis Biologics launches novel ceramic graft substitute made by sintering process of porcine and cancellous bone.
Altis develops novel stitchable fibrillar collagen membrane for use in guided bone regeneration maxillo-facial surgery, neuro-surgery and general orthopedics.
Altis raises R18.9 million (1.25 Million USD) to develop Osteogenic Bone Matrix in spine fusion and alveolar bone regeneration.
Altis Biologics reaches agreement with major Medical Aid companies to cover its graft range for reimbursements.
Altis Biologics relocates its bio-processing laboratories to the Innovation Hub Industrial Complex.
SAHPRA agrees to allow marketing authorization of Altis’ porcine graft BMP complex impregnated collagenous devices.
Altis completes the clinical development of Osteogenic Bone Matrix- trauma, the world’s first injected Bone Morphogenetic Protein (BMP)/ collagen bone graft substitute. OBM is regulated as manipulated Demineralized Bone Matrix graft substitute with guaranteed minimum levels of functional bone protein.
Altis completes pre-clinical development of Osteogenic Bone Matrix.
Altis Biologics and Teknimed (France) reach agreement regarding research and development co-operation related to collagen products and BMP enhanced products.
Altis Biologics and Pentax Corporation (Japan) reach agreement regarding co-development of BMP enhanced products.
Altis Biologics commences the clinical study in humans to determine the safety of Altis OBM in long bone defects.
Altis Biologics obtains approval for a Phase I human clinical study for the use of Altis OBM in patients with traumatic long bone defects.
Altis Biologics receives the South African Department of Science & Technology Minister's award for its valued contribution to biotechnology industry in South Africa.
Altis Biologics receives the Da Vinci Top Technology 100 award for "most promising emerging company"
Altis Biologics manufacturing facility receives a pharmaceutical manufacturing license from the Department of Health of South Africa.
Altis Biologics obtains Good Manufacturing Practice (GMP) certification by the South African Medicines Control Council for Altis OBM.
Altis Biologics facilities are inspected and approved by the South African Pharmacy Council.
Altis Biologics is recognised in the Financial Mail and Financial Times as one of the most promising candidates for listing on the Johannesburg Stock Exchange (JSE).
Altis Biologics completes preclinical studies of Altis OBM, a porcine derived osteogenic bone matrix. Altis OBM is shown to be osteoinductive
Altis Biologics' Southern Africa human-derived BMP licensee launches Endogen IVT in the SA market, an allograft-derived product intended as a bone healing biomaterial.
Altis Biologics and Sojitz Corporation (Japan) sign 3 year agreement whereby Sojitz is appointed as the exclusive representative of Altis Biologics in Japan.
Altis Biologics, in consortium with the Tshwane University of Technology and Bone SA is awarded R14.8 million Innovation Fund Grant to develop porcine bone morphogenetic protein complex as a human bone regeneration biomaterial
Altis Biologics awards a license agreement to Osteogenix (Pty) Ltd
Altis Biologics secures a management contract for the start-up and running of the Centre for Tissue Engineering (CTE), located at the Tshwane University of Technology, Pretoria, South Africa.
A human clinical study shows a 60% healing score for a non-union patient group having a symptomatic period of 26 months, which received human BMP complex prepared according to the high yield technology of Dr Duneas.
co-developed with co-inventor Martina Lutz
